Molecular Targeting Technologies, Inc. and University of Antwerp Begin First-in-Human Study of TDURA Diagnostic for Early Detection of Response to Colon Cancer Therapy
Published: May 11, 2021 WEST CHESTER, Pa.--(BUSINESS WIRE)-- Molecular Targeting Technologies, Inc. (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA ( 99mTc-Duramycin), in patients with advanced colorectal cancer (CRC)*. Colorectal cancer is the third most commonly diagnosed malignancy in the world and the second leading cause of cancer death in the Un...